Skyclarys (Omaveloxolone)
- Skyclarys (Omaveloxolone)
- Medicine Name: Skyclarys
- API: Omaveloxolone
- Dosage Form & Strength: Capsules: 50 mg
- Manufactured By: Reata Pharmaceuticals, Inc.
Skyclarys (omaveloxolone) is a once-daily oral therapeutic drug used for Friedreich’s ataxia (FA) in adults and children/adolescents aged 16 years and older.
Recommended Dosage: The recommended dosage of Skyclarys capsule is 150 mg (three capsules) taken orally (by mouth) once daily. Administer capsules on an empty stomach at least 60 minutes before meal. Swallow capsules whole. Avoid opening, crushing, or chewing the capsules.
If a dose is missed, take the next dose at its scheduled time the following day. Never take a double dose in order to make up for a missed dose.
- Obtain aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, B-type natriuretic peptide (BNP), and lipid parameters before starting Omaveloxolone and throughout treatment.
- Therapy with Skyclarys can cause increased hepatic transaminases (AST and ALT). Monitor AST, ALT, and total bilirubin before initiating therapy with Skyclarys, every month for the initial three months of therapy, and periodically thereafter.
- Treatment with Omaveloxolone 50 mg can cause an elevated BNP, a marker of cardiac function. An increase in BNP may indicate cardiac failure and must prompt an evaluation of cardiac function. Check BNP before initiation of therapy. Monitor respective patients for the signs and symptoms of fluid overload.
- Treatment with this therapeutic drug can be responsible for causing fluctuations in cholesterol. Evaluate lipid parameters before initiation of therapy and monitor periodically during therapy. Manage lipid abnormalities as per clinical guidelines.
- It’s recommended to consider non-hormonal birth control throughout treatment with Skyclarys capsules and for at least 28 days after the final dose. Avoid hormonal birth control methods such as pills, vaginal rings, and implants.
- In case you’re pregnant, want to become pregnant, or breastfeeding while on treatment with Skyclarys 50 mg capsules, contact your healthcare professional about the risks and benefits of using the medicine.
What documents are required to import SKYCLARYS to India?
SKYCLARYS (omaveloxolone) capsules can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients ID proof (issued by the government of India)
The order will be confirmed only after the receipt of:
- A valid prescription from Doctor
- Import permit if applicable
SKYCLARYS (omaveloxolone capsules) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input
- On availability of Skyclarys in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
- Medicine Price
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency
IPN (Indian Pharma Network) can facilitate the supply of SKYCLARYS (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).
Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Skyclarys 50 mg price in India.
We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.
Indian Pharma Network is able to source the SKYCLARYS (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Skyclarys®?
Omaveloxolone is a Generic Name for the trade name drug Skyclarys®.
What is the Manufacturer’s Name of Skyclarys®?
Skyclarys® is manufactured by Reata Pharmaceuticals, Inc.
Is Skyclarys® approved by the FDA?
Yes, Skyclarys® is approved by the FDA. Date of approval: February 28, 2023.
Where can I get Skyclarys® at the best price in India?
To get the best Skyclarys price in India, kindly contact the Indian Pharma Network (a WHO GDP and ISO 9001:2008 certified company). For Skyclarys®, a valid medical prescription is required from a treating physician.
What is the dosage and form of Skyclarys® supplied?
Skyclarys® is supplied as Capsules: 50 mg for oral administration.
What are the most common side effects of Skyclarys®?
The most common side effects of Skyclarys® are headache, elevated liver enzymes (AST/ALT), abdominal pain, fatigue, diarrhea, nausea, and musculoskeletal pain.
How much does Skyclarys® cost in India?
The cost of Skyclarys in India can vary. In order to procure this medicine legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Skyclarys®?
Store the capsules of Skyclarys® at 20-25°C (68-77°F), excursions permitted between 15°C and 30°C (59°F to 86°F).
Is it safe to buy Skyclarys® online in India?
Yes, one can buy Skyclarys online in India at the lowest price from the Indian Pharma Network (IPN) if it is not (yet) registered or available in their country. We can help facilitate the supply of Skyclarys through legal channels.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.